SCHEMBL23701490

SCHEMBL23701490

CC(=NNC(=O)c1ccccc1O)c1ccccc1O

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 2/20 0.74
SMN1; SMN2 Q16637 5/20 0.68
NPC1 O15118 5/20 0.68
RAB9A P51151 4/20 0.68
MAPT P10636 3/20 0.68
ALDH1A1 P00352 2/20 0.68
POLB P06746 1/20 0.68
PKM P14618 1/20 0.68
HPGD P15428 3/20 0.65
LMNA P02545 2/20 0.65
GAA P10253 5/20 0.65
KDM4E B2RXH2 4/20 0.65
CTDSP1 Q9GZU7 1/20 0.63
KMT2A Q03164 6/20 0.60
MEN1 O00255 5/20 0.60
TDP1 Q9NUW8 2/20 0.60
THRB P10828 1/20 0.60
HTT P42858 1/20 0.60
NPSR1 Q6W5P4 1/20 0.60
MAPK1 P28482 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL684855 1.00 KDM1A (0.74) KDM1ASMN1; SMN2NPC1RAB9AMAPT
SCHEMBL683729 0.90 KDM1A (0.67) KDM1ASMN1; SMN2NPC1RAB9AMAPT
SCHEMBL1164808 0.89 KDM1A (0.70) KDM1ASMN1; SMN2NPC1RAB9AMAPT
SCHEMBL1164807 0.89 KDM1A (0.70) KDM1ASMN1; SMN2NPC1RAB9AMAPT
SCHEMBL684651 0.89 KDM1A (0.65) KDM1ASMN1; SMN2NPC1RAB9AMAPT
SCHEMBL18719815 0.89 NPC1 (0.67) KDM1ASMN1; SMN2NPC1RAB9AMAPT
SCHEMBL13835215 0.89 KDM1A (0.65) KDM1ASMN1; SMN2NPC1RAB9AMAPT
SCHEMBL684858 0.89 KDM1A (0.65) KDM1ASMN1; SMN2NPC1RAB9AMAPT
SCHEMBL684489 0.89 NPC1 (0.67) KDM1ASMN1; SMN2NPC1RAB9AMAPT
SCHEMBL684658 0.88 KDM1A (0.83) KDM1ASMN1; SMN2NPC1RAB9AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11427543-B2 Compounds for targeting cancer stem cells THE GENERAL HOSPITAL CORPORATION (US) 2022-08-30 US disclosed
US-20210238140-A1 Compounds for Targeting Cancer Stem Cells THE GENERAL HOSPITAL CORPORATION 2021-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11427543-B2 Compounds for targeting cancer stem cells G3BP1, G3BP2, HMGB2 KDM1A 2810/4885SMN1; SMN2 3949/4885NPC1 1728/4885
US-20210238140-A1 Compounds for Targeting Cancer Stem Cells G3BP1, G3BP2, HMGB2 KDM1A 2810/4885SMN1; SMN2 3949/4885NPC1 1728/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.